Pulmonary Arterial Hypertension Market By Drug Class (PDE-5 Inhibitors, Endothelin Receptor Antagonists (ERAs), SGC Stimulators, Prostacyclin & Prostacyclin Analogs), By Type (Generics, Branded), By Route of Administration (Inhalational, Intravenous/Subcutaneous, Oral), and By Region - Trends, Analysis and Forecast till 2034

Pulmonary Arterial Hypertension (PAH)  Market is the form of broader condition called as pulmonary hypertension, where the increased pressure in vessels are caused by obstruction in small arteries of lungs.

Growing Prevalence of Pulmonary Hypertension to fuel market growth

Growing prevalence of pulmonary hypertension (PH) has become a major factor in target market growth. The increased PH-related mortality is driven by WHO (World Health Organization) groups 2 and 3. Rising adoption of unhealthy lifestyle and consumption of processed food across globe has given rise in chronic diseases which in turn, facilitated the demand for Pulmonary Arterial Hypertension market growth.

For instance, according to CDC WONDER (Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research), the cause of death database for study of age-standardized mortality rates related to PH in United States from 2003 to 2020 is as follows, the total of 126,526 deaths recorded from PH in between 2003 and 2020 and according to study period, the PH-related ASMR was increased from 17.81 per million of population in 2003 to 23.89 million in 2020 with change of percentage of +34%.

Restrains:

However, high cost of PAH drugs and therapies and side-effects of these medications has hampered the demand for Pulmonary Arterial Hypertension Market growth.

Pulmonary Arterial Hypertension Market Segmentation:

Pulmonary Arterial Hypertension Market is segmented based on Drug Class, Type, Route of Administration and Region.

Drug Class Insight

On the basis of Drug Class, Pulmonary Arterial Hypertension Market is segmented into PDE-5 Inhibitors, Endothelin Receptor Antagonists (ERAs), SGC Stimulators, Prostacyclin & Prostacyclin Analogs.

Type Insights

On the basis of Type, Pulmonary Arterial Hypertension Market is segmented into Generics, Branded.

Route of Administration Insights

On the basis of Route of Administration, Pulmonary Arterial Hypertension Market is segmented into Inhalational, Intravenous/Subcutaneous, Oral.

Pulmonary Arterial Hypertension Market Regional Insights:

On region the Pulmonary Arterial Hypertension Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America market is estimated to witness a significantly high revenue share over the forecast period due to rising prevalence of pulmonary hypertension, continuous technological development, increased awareness among people and robust healthcare infrastructure coupled with advanced diagnostic equipment.

Asia Pacific market is estimated to witness a fastest revenue share over the forecast period due to growing population, developing healthcare infrastructure, presence of major pharmaceutical companies such as Cipla Inc., who received FDA (Food and Drug Administration) approval for Ambrisentan Tablets to treat pulmonary arterial hypertension.

Recent Development:

             The New Launched Product News,

• In May 2023, The Janssen Pharmaceutical Company submitted its new drug application to U.S. FDA (Food and Drug Administration) for seeking approval of an investigational single tablet combination therapy of Tadalafil and Macitentan for treating patients with PAH (Pulmonary Arterial Hypertension).

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034.

The key players operating the Pulmonary Arterial Hypertension Market includes, United Therapeutics Corporation, Johnson & Johnson, Bayer, Gilead Sciences Inc., GlaxoSmithKline, Lupin Pharmaceuticals Inc., Novartis, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries, Inc., Viatris Inc., and others.

• United Therapeutics Corporation
• Johnson & Johnson
• Bayer
• Gilead Sciences Inc.
• GlaxoSmithKline
• Lupin Pharmaceuticals Inc.
• Novartis
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries, Inc.
• Viatris Inc.

1. The Last Word
   • Future Impact
   • About Us
   • Contact